Aveo Pharmaceuticals, Inc.
AVEONext catalyst
Ficlatuzumab
Metastatic Head-and-neck Squamous-cell Carcinoma
Get an email about AVEO's next catalysts
Track Aveo Pharmaceuticals (AVEO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 4 past
Ficlatuzumab Phase 3 Est. Readout (FIERCE-HN)
Primary completion for Ficlatuzumab trial (NCT06064877) in Metastatic Head-and-neck Squamous-cell Carcinoma
SourceMarket Overview
Stock performance and key metrics
Samalizumab (BAML-16-001-S1)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Ficlatuzumab
Metastatic Head-and-neck Squamous-cell Carcinoma
Tivozanib
Renal Cell Carcinoma
Tivozanib hydrochloride
Carcinoma, Renal Cell
Daunorubicin or Idarubicin (BAML-16-001-S25/HO181)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
tivozanib (AV-951)
Advanced Renal Cell Carcinoma
Decitabine (BAML-16-001-S5)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
AZD5991 (BAML-16-001-S18)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Bleximenib (BAML-16-001-S25/HO181)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Revumenib (BAML-16-001-S26/HO177)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Daunorubicin (BAML-16-001-S1)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Entospletinib (BAML-16-001-S4)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Gilteritinib (BAML-16-001-S8 Group 1)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
AG-120 (BAML-16-001-S16)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Decitabine (BAML-16-001-S8 Group 2)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
ZE46-0134 (BAML-16-001-S21 Group 1)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Pevonedistat (BAML-16-001-S9)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
TP-0903 (BAML-16-001-S14)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Cytarabine (BAML-16-001-S25/HO181)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Entospletinib (BAML-16-001-S6)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Decitabine (BAML-16-001-S8 Group 1)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
AZD5153 (BAML-16-001-S10)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Gilteritinib (BAML-16-001-S8 Group 2)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
BI 836858 (BAML-16-001-S2)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
AG-221 (BAML-16-001-S3)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Daunorubicin (BAML-16-001-S6)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Decitabine (BAML-16-001-S14)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
ZE46-0134 (BAML-16-001-S21 Group 2)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Cytarabine (BAML-16-001-S1)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Entospletinib (BAML-16-001-S5)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Cytarabine (BAML-16-001-S6)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
SNDX-5613 (BAML-16-001-S17)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
ficlatuzumab (BAML-16-001-S24)
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
mFOLFOX6
Colorectal Cancer
AV-299 + gefitinib
Carcinoma, Non-Small Cell-Lung
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Samalizumab (BAML-16-001-S1) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
Ficlatuzumab | Phase 3 | Metastatic Head-and-neck Squamous-cell Carcinoma | - | - |
Tivozanib | Phase 3 | Renal Cell Carcinoma | - | - |
Tivozanib hydrochloride | Phase 3 | Carcinoma, Renal Cell | - | - |
Daunorubicin or Idarubicin (BAML-16-001-S25/HO181) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
tivozanib (AV-951) | Phase 3 | Advanced Renal Cell Carcinoma | - | - |
Decitabine (BAML-16-001-S5) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
AZD5991 (BAML-16-001-S18) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
Bleximenib (BAML-16-001-S25/HO181) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
Revumenib (BAML-16-001-S26/HO177) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
Daunorubicin (BAML-16-001-S1) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
Entospletinib (BAML-16-001-S4) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
Gilteritinib (BAML-16-001-S8 Group 1) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
AG-120 (BAML-16-001-S16) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
Decitabine (BAML-16-001-S8 Group 2) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
ZE46-0134 (BAML-16-001-S21 Group 1) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
Pevonedistat (BAML-16-001-S9) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
TP-0903 (BAML-16-001-S14) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
Cytarabine (BAML-16-001-S25/HO181) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
Entospletinib (BAML-16-001-S6) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
Decitabine (BAML-16-001-S8 Group 1) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
AZD5153 (BAML-16-001-S10) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
Gilteritinib (BAML-16-001-S8 Group 2) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
BI 836858 (BAML-16-001-S2) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
AG-221 (BAML-16-001-S3) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
Daunorubicin (BAML-16-001-S6) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
Decitabine (BAML-16-001-S14) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
ZE46-0134 (BAML-16-001-S21 Group 2) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
Cytarabine (BAML-16-001-S1) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
Entospletinib (BAML-16-001-S5) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
Cytarabine (BAML-16-001-S6) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
SNDX-5613 (BAML-16-001-S17) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
ficlatuzumab (BAML-16-001-S24) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | - | - |
mFOLFOX6 | Phase 2 | Colorectal Cancer | - | - |
AV-299 + gefitinib | Phase 2 | Carcinoma, Non-Small Cell-Lung | - | - |
Frequently asked questions
What is in Aveo Pharmaceuticals, Inc.'s drug pipeline?β
CatalystAlert tracks 35 drug candidates in Aveo Pharmaceuticals, Inc.'s (AVEO) pipeline across Phase 3, Phase 2. Its lead program is Ficlatuzumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Aveo Pharmaceuticals, Inc.'s next FDA catalyst?β
Aveo Pharmaceuticals, Inc.'s (AVEO) next tracked catalyst is a Phase 3 readout expected August 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AVEO biotech catalysts?β
Add AVEO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Aveo Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
